BUY Aurobindo Pharma — Kunal Saraogi, 10 Aug 2026

BUYAurobindo Pharma

Aurobindo Pharma share price target & all analyst calls

byKunal SaraogiHorizon: NA (inferred Swing (≤2wk))10 Aug 2026via Zee Business (Live)

Entry₹1,668Inferred

Target₹1,695

Total upside +1.62%

Stop loss₹1,635-1.98% risk

Exit₹1,63514 Aug 2026, 9:50 am

Stop-loss hit-1.98%

Follow Kunal Saraogi for new calls(35% target hit, 52 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 1 active Swing call on AUROPHARMA See 142 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 14 Aug 2026

12 supporting2 neutral1 opposing

Supports the BUY call (12)

Aurobindo Pharma Ltd has incorporated a new wholly owned subsidiary in India named 'Auropharm Overseas Limited'. The subsidiary will undertake manufacturing and marketing operations.

BSE · Company Update·13 Aug · today

Aurobindo Pharma Expands Margins as Sales Grow

NewsGoogle News·12 Aug · yesterday

Results: Aurobindo Pharma Limited Exceeded Expectations And The Consensus Has Updated Its Estimates

NewsGoogle News·8 Aug · 6d ago

Aurobindo Pharma rises 3% after Q1 beat; HDFC Securities retains 'Add', Axis Securities cuts to 'Hold'

NewsGoogle News·7 Aug · 6d ago

Hold Aurobindo Pharma; target of Rs 1600: Prabhudas Lilladher

NewsGoogle News·7 Aug · 6d ago

Neutral / worth noting (2)

Aurobindo Pharma has announced its unaudited financial results for the first quarter ended June 30, 2026. The company has provided a press release detailing these results.

NSE · Press Release·5 Aug · 1w ago

Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·5 Aug · 1w ago

Weighs against the BUY call (1)

1 advisor has an active short-term SELL call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·6 Aug · 1w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Kunal Saraogi

Every call and its outcome